Síntesis y actividad antiproliferativa de una mezcla de derivados de (⁺ ̸ ₋) 7-cloro-(4-tioalquilquinolina). Inducción de apoptosis y daño sobre el ADN/ARN
Synthesis and antiproliferative activity of a mixture (⁺ ̸ ₋) 7-chloro-(4-thioalkylquinoline) derivatives. Inducing apoptosis and DNA/RNA damage
Síntese e atividade antiproliferativa de uma mistura de derivados de (⁺ ̸ ₋) 7-cloro-(4-tioalquilquinolina). Indução de apoptose e dano de DNA/RNA
DOI:
https://doi.org/10.15446/rev.colomb.quim.v52n1.110787Palabras clave:
cáncer; ciclo celular; derivados sulfanilos; mezcla racémica (es)câncer; ciclo celular; derivados sulfanilos; mezcla racémica (pt)
cancer; cell cycle; sulfanyl derivatives; racemic mixture. (en)
Después de las enfermedades cardiovasculares, el cáncer una patología no transmisible ha sido considerada como la segunda causa de muertes cada año a nivel global y como la barrera más importante para aumentar la esperanza de vida en el siglo 21. Se han alcanzado avances de gran relevancia en su prevención y tratamiento, sin embargo, existe aún un largo camino por recorrer para alcanzar un tratamiento efectivo para cada tipo de cáncer. En este trabajo se describen enfoques de reposicionamiento y síntesis de moléculas hibridas con potencial actividad antineoplásica. Para obtener el aldehído intermediario clave, se empleó la metodología de oxidación de Dess-Martin, que fue acoplado con las cetonas correspondientes usando LDA. Los compuestos híbridos finales fueron obtenidos como una mezcla racémica. La actividad antiproliferativa in vitro de los compuestos finales se evaluó frente a ocho líneas celulares derivadas de tumores sólidos humanos, y cuatro líneas celulares no cancerosas. El compuesto 11d resulto ser el más efectivo y con mayor índice de seguridad. Los resultados sugirieron que estos compuestos podrían bloquear el ciclo celular e inducir la apoptosis y la muerte en las células CCRF-CEM de forma dependiente de la dosis in vitro.
After cardiovascular diseases, cancer, a non-communicable pathology, has been considered the second cause of death each year globally and as the most important barrier to increasing life expectancy in the 21st century. Advances of great relevance have been made in its prevention and treatment, however, there is still a long way to go to achieve an effective treatment for each type of cancer. This paper describes approaches to reposition and synthesis of hybrid molecules with potential antineoplastic activity. To obtain the key intermediate aldehyde, the Dess-Martin oxidation methodology was used, which was coupled with the corresponding ketones using LDA. The final hybrid compounds were obtained as a racemic mixture. The in vitro antiproliferative activity of the final compounds was evaluated against eight cell lines derived from human solid tumors, and four non-cancerous cell lines. The compound 11d turned out to be the most effective and with the highest safety index. The results suggested that these compounds could block the cell cycle and induce apoptosis and death in CCRF-CEM cells in a dose-dependent manner in vitro.
Depois das doenças cardiovasculares, o câncer, uma patologia não transmissível, tem sido considerado como a segunda causa de mortes a cada ano em todo o mundo e como a barreira mais importante para o aumento da expectativa de vida no século 21. Avanços de grande relevância têm sido feitos na sua prevenção e tratamento, no entanto, ainda há um longo caminho a percorrer para alcançar um tratamento eficaz para cada tipo de câncer. Este artigo descreve abordagens para o reposicionamento e síntese de moléculas híbridas com potencial atividade antineoplásica. Para a obtenção do aldeído intermediário chave, foi utilizada a metodologia de oxidação de Dess-Martin, que foi acoplada com as cetonas correspondentes usando LDA. Os compostos híbridos finais foram obtidos como uma mistura racêmica. A atividade antiproliferativa in vitro dos compostos finais foi avaliada contra oito linhagens celulares derivadas de tumores sólidos humanos e quatro linhagens celulares não cancerosas. O composto 11d revelou-se o mais eficaz e com o maior índice de segurança. Os resultados sugeriram que estes compostos poderiam bloquear o ciclo celular e induzir apoptose e morte em células CCRF-CEM de forma dose-dependente in vitro.
Referencias
World Health Organization (WHO), https://www.who.int/news-room/fact-sheets/detail/ cancer (2022). (Accesada 02–08–2023).
R. L. Siegel, K. D. Miller, N. S. Wagle, A. Jemal, Cancer statistics, 2023. CA. Cancer J. Clin. 73, (1), 17–48, 2023. https://doi.org/10.3322/caac.21763.
M. Xi, T. Chen, C. Wu, X. Gao, Y. Wu, X. Luo, K. Du, L. Yu, T. Cai, R. Shen, H. Sunet, CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Eur. J. Med. Chem. 164, 77-91, 2019. https://doi.org/10.1016/j.ejmech.2018.11.076.
D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, (5), 646–674, 2011. https://doi.org/10.1016/j.cell.2011.02.013.
F. S. Liu, Mechanisms of chemotherapeutic drug resistance in cancer therapy–a quick review. Taiwan. J. Obstet. Gynecol. 48, (3), 239–244, 2009. https://doi.org/10.1016/S1028-4559(09)60296-5.
J. Iqbal, B.A. Abbasi, T. Mahmood, S. Kanwal, B. Ali, S.A. Shah, A.T. Khalil, Plant-derived anticancer agents: a green anticancer approach, Asian Pac. J. Trop. Biomed. 7, (12), 1129–1150, 2017. https://doi.org/10.1016/j.apjtb.2017.10.016.
MAA. Al-Bari, Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 70, (6), 1608–1621, 2015. https://doi.org/10.1093/jac/dkv018.
D. Plantone, T. Koudriavtseva, Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-review. Clin. Drug Invest. 38, (8), 653–671, 2018. https://doi.org/10.1007/s40261-018-0656-y.
A. M. Shukla, A. W. Shukla, Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context. 8, 2019-9-1, 2019. https://doi.org/10.7573/dic.2019-9-1.
C. Verbaanderd, H. Maes, M. B. Schaaf, V. P. Sukhatme, P. Pantziarka, V. Sukhatme, P. Agostinis, G. Bouche, Repurposing Drugs in Oncology (ReDO)–chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience 11, 781, 2017. https://doi.org/10.3332/ecancer.2017.781.
P. Samaras, M. Tusup, TDL. Nguyen-Kim, B. Seifert, H. Bachmann, R. von Moos, A. Knuth, S. Pascolo, Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother. Pharmacol. 80, (5), 1005–1012, 2017. https://doi.org/10.1007/s00280-017-3446-y.
S. Fortin, G. Bérubé. Advances in the development of hybrid anticancer drugs. Expert Opin. Drug Discov. 8, (8), 1029–1047, 2013. https://doi.org/10.1517/17460441.2013.798296.
J. A. Marinho, D. S. Martins Guimaraes, N. Glanzmann, G. de Almeida-Pimentel, K. I. da Cost Nunes, H. M. Gualberto-Pereira, M. Navarro, F. de Pilla-Varotti, D. A. da Silva, C. Abramo, In vitro and in vivo antiplasmodial activity of novel quinoline derivative compounds by molecular hybridization. Eur. J. Med. Chem. 215, 113271, 2021. https://doi.org/10.1016/j.ejmech.2021.113271.
R. Morphy, Z. Rankovic, Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48, (21), 6523–6543. 2005. https://doi.org/10.1021/jm058225d.
F. W. Muregi, A. Ishih, Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design. Drug Dev. Res. 71, (1) 20–32, 2010. https://doi.org/10.1002/ddr.20345.
B. Meunier, Hybrid molecules with a dual mode of action: Dream or reality?. Acc. Chem. Res. 41, (1), 69–77, 2008. https://doi.org/10.1021/ar7000843.
A. Pawełczyk, K. Sowa-Kasprzak, D. Olender, L. Zaprutko, Molecular consortia - various structural and synthetic concepts for more effective therapeutics synthesis. Int. J. Mol. Sci. 19, (4), 1104–1123, 2018. https://doi.org/10.3390/ijms19041104.
H. M. Sampath, L. Herrmann, S. B. Tsogoeva, Structural hybridization as a facile approach to new drug candidates. Bioor. Med. Chem. Lett. 30, (23), 127514, 2020, https://doi.org/10.1016/j.bmcl.2020.127514.
O. M. Soltan, M. F. Shoman, S. A. Abdel-Aziz, A. Narumi, H. Konno, M. Abdel-Aziz, Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. Eur. J. Med. Chem. 225, 113768, 2021. https://doi.org/10.1016/j.ejmech.2021.113768.
O. Afzal, S. Kumar, R. Haider, R. Ali, R. Kumar, M. Jaggi, S. Bawa, A review of the anticancer potential of bioactive heterocycle quinoline. Eur. J. Med. Chem. 97, 871–910, 2015, http://dx.doi.org/10.1016/j.ejmech.2014.07.044.
R. Kaur, K. Kumar, Synthetic and medicinal perspective of quinolines as antiviral agents. Eur. J. Med. Chem. 215, 113220, 2021. https://doi.org/10.1016/j.ejmech.2021.113220.
B.S. Matada, R. Pattanashettar, N.G. Yernale, A comprehensive review on the biological interest of quinoline and its derivatives. Bioorg. Med. Chem. 32, 115973, 2021, https://doi.org/10.1016/j.bmc.2020.115973.
S. Mah, J.H. Park, H-Y. Jung, K. Ahn, S. Choi, H.S. Tae, K.H. Jung, J.K. Rho, J.C. Lee, S-S. Hong, S. Hong, Identification of 4‑phenoxyquinoline based inhibitors for L1196M mutant of anaplastic lymphoma kinase by structure-based design. J. Med. Chem. 60, (22), 9205–9221, 2017, https://doi.org/10.1021/acs.jmedchem.7b01039.
J. R. Rodrigues, J. Charris, R. Ferrer, N. Gamboa, J. Ángel, B. Nitzsche, M. Hoepfner, M. Lein, K. Jung, C. Abramjuk, Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo. Invest. New Drugs 30, (4), 1426–1433, 2012. https://doi.org/10.1007/s10637-011-9716-3.
J. A. Romero, M. E. Acosta, N. D. Gamboa, M. R. Mijares, J. B. De Sanctis, J. E. Charris, Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate. Bioorg. Med. Chem. 26, (4), 815–823, 2018. https://doi.org/10.1016/j.bmc.2017.12.022.
H. Ramírez, E. Fernandez, J. Rodrigues, S. Mayora, G. Martínez, C. Celis, J. B. De Sanctis, M. Mijares, J. Charris, Synthesis and antimalarial and anticancer evaluation of 7‐chlorquinoline‐4‐thiazoleacetic derivatives containing aryl hydrazide moieties. Arch. Pharm. 354, (7), e2100002, 2021. https://doi.org/10.1002/ardp.202100002.
S. Chitra, N. Paul, S. Muthusubramanian, P. Manisankar, P. Yogeeswari, D. Sriram, Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies. Eur. J. Med. Chem. 46, (10), 4897–4903, 2011. https://doi.org/10.1016/j.ejmech.2011.07.046.
Y. H. Kim, J. M. Kauffman, W. O. Foye, Synthesis and Antileukemic Activity of 2-(2-Methylthio-2 -aminovinyl)-1-methylquinolinium Iodides. J. Pharm. Scienc. 72, (11), 1356-1358, 1983. https://doi.org/10.1002/jps.2600721132.
Z. Cai, W. Zhoua, L. Sun, Synthesis and HMG CoA reductase inhibition of 4-thiophenylquinolines as potential hypocholesterolemic agents. Bioorg. Med. Chem. 15, (24), 7809–7829, 2007. https://doi.org/10.1016/j.bmc.2007.08.044.
E. S . Coimbra, L. M. Antinarelli, N. P. Silva, I. O. Souza, R. S. Meinel, M. N. Rocha, R. P. Soares, A. D. da Silva, Quinoline derivatives: Synthesis, leishmanicidal activity and involvement of mitochondrial oxidative stress as mechanism of action. Chem. Biol. Interact. 260, 50–57, 2016. https://doi.org/10.1016/j.cbi.2016.10.017.
E. Lukevics, E. Abele, P. Arsenyan, R. Abele, K. Rubina, I. Shestakova, I. Domracheva, V. Vologdina, Synthesis and cytotoxicity of silicon containing pyridine and quinoline sulfides. Met. Based Drugs 9, (1, 2) 45–51, 2002. https://doi.org/10.1155/MBD.2002.45.
W. Mól, M. Matyja, B. Filip, J. Wietrzyk, S. Boryczka, Synthesis and antiproliferative activity in vitro of novel (2-butynyl)thioquinolines. Bioorg. Med. Chem. 16, (17), 8136–8141, 2008. https://doi.org/10.1016/j.bmc.2008.07.047.
H. Sugimoto, Y Iimura, Y. Yamanishi, K. Yamatsu, Synthesis and Structure-Activity Relationships of acetylcholinesterase inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38, (24), 4821– 4829, 1995. https://doi.org/10.1021/jm00024a009.
H. O. Saxena, U. Faridi, S. Srivastava, J. K. Kumar, M. P. Darokar, S. Luqman, C. S. Chanotiya, V. Krishna, A. S. Negi, S. P. S. Khanuja, Gallic acid-based indanone derivatives as anticancer agents. Bioorg. Med. Chem. Lett. 18, (14), 3914–3918, 2008. https://doi.org/10.1016/j.bmcl.2008.06.039
A. I. Syrchina, A. A. Semenov, Natural indanones. Chem. Nat. Compd. 18, 1–11, 1982. https://doi.org/10.1007/BF00581584.
N. V. Kovganko, Z. N. Kashkan and S. N. Krivenok, Bioactive compounds of the flora of belarus. 4. pterosins a and b from Pteridium aquilinum. Chem. Nat. Compd. 40, 227–229, 2004. https://doi.org/10.1023/B:CONC.0000039129.46159.ce.
X. Ge, G. Ye, P. Li, W.-J. Tang, J.-L. Gao, W.-M. Zhao, Cytotoxic Diterpenoids and Sesquiterpenoids from Pteris multifida. J. Nat. Prod. 71, (2), 227–231, 2008. https://doi.org/10.1021/np0706421.
H. Sheridan, N. Frankish, R. Farrell, Synthesis and antispasmodic activity of analogues of natural pterosins. Eur. J. Med. Chem. 34, (11), 953–966, 1999. https://doi.org/10.1016/S0223-5234(99)00113-0.
J. C. Menezes, Arylidene indanone scaffold: medicinal chemistry and structure–activity relationship view. RSC Adv. 7, 9357–9372, 2017. https://doi.org/10.1039/c6ra28613e.
J. E. Gutiérrez, E. Fernandez-Moreira, M. E. Acosta, H. Ramírez. J. E. Charris, Optimization of the synthesis, in silico ADME/Tox profiling studies, and evaluation of the antimalarial activity of (7-chloroquinolin-4-ylthio)alkylbenzoate derivatives. J. Chem. Res. 47, (3), https://doi.org/10.1177/17475198231175326.
P. A. Peixoto, R. Severin, C-C. Tseng, D. Y-K, Chen, Formal asymmetric synthesis of echinopine A and B. Angew. Chem. Int. Ed. 50, (13), 3013–3016, 2011. https://doi.org/10.1002/anie.201008000.
Y. J. Kim, M. P. Bernstein, A. S. Galiano, F. E. Romesberg, P. G. Williard, D. J. Fuller, A. T. Harrison, D. B. Collum, On the structure and reactivity of Lithium Diisopropylamide (LDA) in hydrocarbon solutions. Formation of unsolvanted ketone, ester, and carboxamide enolates. J. Org. Chem. 56, (14), 4435–4439, 1991. https://doi.org/10.1021/jo00014a019.
O. Provot, J. F. Berrien, H. Moskowitz, J. Mayrargue, Trifluoromethy ketones chemistry: efficient access to silyl enol ethers or silyl carbinds using lithium diisopropylamide. J. Fluorine Chem. 86, (2), 185–186, 1997. https://doi.org/10.1016/S0022-1139(97)00098-5.
Y. Yamamoto, Y. Yasuda, H. Oulyadi, J. Maddaluno, K. Tomioka, NMR studies of a ternary complex reagent of lithium ester enolate, chiral diether, and lithium diisopropylamide in an asymmetri Michael reaction. Tetrahedron 66, (13), 2470–2473, 2010. https://doi.org/10.1016/j.tet.2010.01.072.
M. Jurášek, P. Džubák, S. Rimpelová, D. Sedlák, P. Konečný, I. Frydrych, S. Gurská, M. Hajdúch, K. Bogdanová, M. Kolář, M. T. Müller, E. Kmoníčková, T. Ruml, J. Harmatha, P. B. Drašar. Trilobolide-steroid hybrids: Synthesis, cytotoxic and antimycobacterial activity. Steroids 117, 97–104, 2017. https://doi.org/10.1016/j.steroids.2016.08.011.
J. Řehulka, K. Vychodilová, P. Krejčí, S. Gurská, P. Hradil, M. Hajdúch, P. Džubák, J. Hlaváč, Fluorinated derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone as tubulin polymerization inhibitors. Eur. J. Med. Chem. 192, 112176, 2020. https://doi.org/10.1016/j.ejmech.2020.112176.
S. Rimpelová, T. Zimmermann, P. B. Drašar, B. Dolenský, J. Bejček, E. Kmoníčková, P. Cihlárová, S. Gurská, L. Kuklíková, M. Hajdúch, T. Ruml, L. Opletal, P. Džubák, M. Jurášek, Steroid glycosides hyrcanoside and deglucohyrcanoside: On isolation, structural identification, and anticáncer activity. Foods 10, (1), 136, 2021. https://doi.org/10.3390/foods10010136.
P. Džubak, S. Gurská, K. Bogdanová, D. Uhríková, N. Kanjaková, S. Combet, T. Klunda, M. Kolář, M. Hajdúch, M. Poláková, Antimicrobial and cytotoxic activity of (thio)alkyl hexopyranosides, nonionic glycolipid mimetics. Carbohydr. Res. 488, 107905, 2020. https://doi.org/10.1016/j.carres.2019.107905.
J. E. Gutiérrez, E. Fernandez-Moreira, M. A. Rodríguez, M. R. Mijares, J. B. De Sanctis, S. Gurská, P. Džubák, M. Hajdůch, J. Bruno-Colmenarez, L. Rojas, D. Deffieux, L. Pouységu, S. Quideau, J. Charris, H. Ramírez. Novel 7-Chloro-(4-thioalkylquinoline) derivatives: Synthesis and antiproliferative activity through inducing apoptosis and DNA/RNA damage. Pharmaceuticals 15, 1234, 2022. https://doi.org/10.3390/ph15101234.
K. Sasaki, N. H. Tsuno, E. Sunami, G. Tsurita, K. Kawai, Y. Okaji, T. Nishikawa, Y. Shuno, K. Hongo, M. Hiyoshi, M. Kaneko, J. Kitayama, K. Takahashi, H. Nagawa, Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 10, 370, 2010. https://doi.org/10.1186/1471-2407-10-370.
H. Monma, Y Iida, T. Moritani, T. Okimoto, R. Tanino, Y. Tajima, M. Harada, Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells. PLoS ONE 13, (3), e0193990, 2018. https://doi.org/10.1371/journal.pone.0193990.
T. Hu, P. Li, Z. Luo, X. Chen, J. Zhang, C. Wang, P. Chen, Z. Dong, Chloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivo. Oncol. Rep. 35, (1), 43–49, 2016. https://doi.org/10.3892/or.2015.4380.
L. Jia, J. Wang, T. Wu, J. Wu, J. Ling, B. Cheng, In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma. Mol. Med. Rep. 16, 5779–5786, 2017, https://doi.org/10.3892/mmr.2017.7342.
P. Jiang, Y. Zhao, W. Shi, X. Deng, G. Xie, Y. Mao, Z. Li, Y. Zheng, S. Yang, Y. Wei, Cell Growth Inhibition, G2/M Cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. Cell Physiol. Biochem. 22, (5,6), 431–440, 2008. https://doi.org/10.1159/000185488.
Cómo citar
IEEE
ACM
ACS
APA
ABNT
Chicago
Harvard
MLA
Turabian
Vancouver
Descargar cita
Licencia
Derechos de autor 2023 Jaime Charris Charris

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC. Atribución 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
